Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)

Hepatitis C Clinical Trial

Official title:

A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02601573
• Other study ID #: 5172-083
• Secondary ID: 2015-003187-37MK
• Status: Completed
• Phase: Phase 2
• Start date: January 5, 2016
• Est. completion date: January 6, 2017

Study information

• Verified date: August 2019
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, multi-site, open-label trial of the co-administration of a fixed-dose combination (FDC) of EBR 50 mg + GZR (100 mg) (EBR/GZR) and SOF 400 mg, with and without RBV, in treatment-naïve (TN) and treatment-experienced (TE) participants with chronic HCV GT3 infection with compensated cirrhosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: January 6, 2017
• Est. primary completion date: October 18, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• has HCV RNA (>= 10,000 IU/mL in peripheral blood) at screening

• has documented HCV GT3 (with no evidence of non-typeable or mixed GT infection)

• has compensated cirrhosis of the liver

• has liver imaging within 6 months of Day 1 with no evidence of hepatocellular carcinoma (HCC)

• is either HCV TN or TE (i.e., has documented prior virologic failure or intolerance to peg-interferon/ribavirin)

• is otherwise healthy as determined by medical history, physical examination, electrocardiogram (ECG), and clinical laboratory measurements

• has compensated cirrhosis of the liver

• is TN or TE (i.e., documented prior virologic failure or intolerance to peg-interferon/ribavirin)

• is not of reproductive potential, or agrees to not impregnate a partner or become pregnant for at least 2 weeks prior to the first dose of study drug, and for 7 months after the final dose of study drug (or longer if dictated by local regulations)

Exclusion Criteria:

• has previously received one or more doses of a direct-acting antiviral (DAA)

• has evidence of decompensated liver disease

• is coinfected with hepatitis B (hepatitis B surface antigen [HBsAg] positive)

• has a recent (within 5 years) history of malignancy or is under evaluation for HCC or other suspected malignancy

• is currently or has participated (within past 30 days) in a study with an investigational compound

• has clinically-relevant drug or alcohol abuse within the past 12 months of screening

• is a female and is pregnant or breast-feeding

• is a male whose female partner is/are pregnant

• has any of the following:

• organ transplants

• poor venous access

• history of gastric surgery or malabsorption disorder

• current or history of clinically significant cardiac abnormalities or dysfunction

• chronic pulmonary disease

• hemoglobinopathy

• history of hospitalization within 3 months prior to enrollment

• medical or surgical condition that may result in need for hospitalization during the course of the study

• any condition requiring, or likely to require, chronic systemic administration of corticosteroids, tumor necrosis factor (TNF) antagonists, or other immunosuppresant drugs during the course of the study

• any condition, prestudy laboratory or ECG abnormality, or history of any illness, which could confound results of the study or pose additional risks in administering study drugs in the opinion of the investigator

• has a life-threatening serious AE (SAE) during the screening period

• has evidence of history of chronic hepatitis not caused by HCV

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis C

Intervention

Drug:
• Grazoprevir
GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
• Elbasvir
EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
• Ribavirin
RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
• Sofosbuvir
SOF 400 mg tablet taken q.d. by mouth in the morning with food.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Achieving SVR12 (Sustained Virologic Response 12 Weeks After the End of All Study Therapy)	The percentage of participants achieving SVR12 (i.e., HCV ribnonucleic acid [RNA] < Lower Limit of Quantification [LLOQ] 12 weeks after completing study treatment) was determined. Plasma HCV RNA levels were determined with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.	Up to Week 28
Primary	Percentage of Participants Experiencing an Adverse Event (AE)	An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.	Up to 18 weeks (up to 2 weeks after completion of study treatment)
Primary	Percentage of Participants Discontinuing From Study Therapy Due to an AE	An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.	Up to 16 weeks
Secondary	Percentage of Participants Achieving SVR24 (Sustained Virologic Response 24 Weeks After the End of All Study Therapy)	The percentage of participants achieving SVR24 (i.e., HCV RNA < LLOQ 24 weeks after completing study treatment) was determined. Plasma HCV RNA levels were determined with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.	Up to Week 40